Target discovery represents a pivotal phase in the design of successful cancer treatments with an emphasis on uncovering molecular targets that promote tumor growth and survival. The session "Target Discovery" highlights novel strategies, technologies, and methods for discovering actionable targets for precision oncology.".
By genetic, proteomic, and transcriptomic studies, scientists can detect oncogenes, tumor suppressors, signaling pathways, and epigenetic regulators that drive cancer development. Knowing these targets facilitates the design of treatments that selectively block cancer-promoting processes without harming normal tissues. High-throughput screening, CRISPR-based functional genomics, and computation modeling are some of the techniques employed to speed target discovery.
The session also examines how target discovery guides drug development, biomarker discovery, and combination therapy design. By connecting molecular targets to clinical phenotypes, scientists can prioritize interventions with the greatest therapeutic value and minimize the risk of resistance.
Participants will learn about the principles, methods, and applications of target discovery in oncology. This session emphasizes the significance of identifying new cancer targets to fuel innovation, enable personalized medicine, and create safer and more effective therapies that enhance patient outcomes and propel the advancement of precision oncology.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
